Journal article
Use of folic acid-containing supplements after a diagnosis of colorectal cancer in the colon cancer family registry
RS Holmes, Y Zheng, JA Baron, L Li, G McKeown-Eyssen, PA Newcomb, MC Stern, RW Haile, WM Grady, JD Potter, L Le Marchand, PT Campbell, JC Figueiredo, PJ Limburg, MA Jenkins, JL Hopper, CM Ulrich
Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2010
Abstract
Background: Supplement use among cancer patients is high, and folic acid intake in particular may adversely affect the progression of colorectal cancer. Few studies have evaluated the use of folic acid-containing supplements (FAS) and its predictors in colorectal cancer patients. Objective: To assess the use of FAS, change in use, and its predictors after colorectal cancer diagnosis. Design: We used logistic regression models to investigate predictors of FAS use and its initiation after colorectal cancer diagnosis in 1,092 patients recruited through the Colon Cancer Family Registry. Results: The prevalence of FAS use was 35.4% before and 55.1% after colorectal cancer diagnosis (P = 0.004). W..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
NIH grants: R01C105437, R25CA94880 and 5T32DK007742. This work was supported by the National Cancer Institute, NIH under RFA # CA-95-011 and through cooperative agreements with members of the C-CFR and Principal Investigators.